

# Abstract Topics

**Abstract Submission Is Open!**

*The submission deadline is 17 September 2024.*

## List of accepted Abstract Topics:

- **Real-World Experience, Novel Clinical Approaches, and Combination Therapies:** Potential synergy between engineered lymphocytes & other treatment modalities will be demonstrated.
- **Superpowered Lymphocytes:** Learn more about the engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.
- **Non-Viral CAR/TCR Gene Targeting:** Recent advancements in promoting integration into lymphocyte genomes by means of nucleases or transposons.
- **CAR/TCR mRNA Therapies:** Exploring the therapeutic effects of transient CAR/TCR expression using mRNA delivery.
- **Universal Donor Cells & Advanced TCR Engineering:** A deeper look at allogeneic therapies, including those applying genome editing technologies.
- **Updated Clinical Data:** First, look at post marketing real world data on the approved T cell therapies.
- **Beyond Alpha-Beta T Cells:** Discuss the engineering of alternative leukocytes, including Gamma-Delta T cells, iNKT cells, NK cells, B cells, and macrophages.
- **Targeting Non-Malignant Diseases:** Targeting non-malignant diseases, including infectious diseases, auto-

immune diseases, cardiovascular diseases, genetic disorders, and more.

- **In Vivo and Bedside T Cell Engineering:** Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines, and preconditioning requirements.

[SUBMIT HERE](#)

All accepted abstracts from ICLE 2025 will be published in

*Human Gene Therapy*

*(Impact Factor 4.2\*)*

\*2022 Journal Citation Reports™ (Clarivate, 2023)

CiteScore™: 7

[LEARN MORE](#)